Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Pierre Reusser is active.

Publication


Featured researches published by Pierre Reusser.


The Journal of Infectious Diseases | 1999

Cytomegalovirus (CMV)—Specific T Cell Immunity after Renal Transplantation Mediates Protection from CMV Disease by Limiting the Systemic Virus Load

Pierre Reusser; Gieri Cathomas; Rudolf Attenhofer; Michael Tamm; Gilbert Thiel

The role of cytomegalovirus (CMV)-specific cytotoxic T lymphocytes (CTLs) and T helper cells (Th) in controlling CMV infection, as detected by antigenemia assay and polymerase chain reaction (PCR) in blood leukocytes, and CMV disease was investigated in 20 renal transplant recipients. Within 3 months after transplant, CMV-specific CTL and Th responses were demonstrable in 11 (55%) and 15 (75%) patients, respectively; CMV infection was detected by antigenemia and PCR in 19 (95%) patients each. During the month of first CMV detection, there was an inverse correlation between CTL response and antigenemia at >/=20 positive cells/105 leukocytes (P=.007) but no association with lower antigenemia levels or PCR positivity. CMV disease developed in 7 (35%) patients and was associated with high-level antigenemia but was inversely correlated with detection of CTLs (P=.04). After renal transplantation, CMV-specific CTLs limit the systemic virus load as reflected by antigenemia levels and thereby mediate protection from CMV disease.


Annals of the New York Academy of Sciences | 1991

Development of a treatment regimen for human cytomegalovirus (CMV) infection in bone marrow transplantation recipients by adoptive transfer of donor-derived CMV-specific T cell clones expanded in vitro.

Philip D. Greenberg; Pierre Reusser; J. M. Goodrich; Stanley R. Riddell

CMV infection represents a major cause of morbidity and mortality in immunosuppressed bone marrow transplant (BMT) recipients. Life-threatening CMV infection was found to occur only in patients who did not develop a CMV-specific CD8+ Tc response. Therefore, methods to clone and expand CMV-specific Tc were developed to facilitate analysis of the specificity of the CD8+ Tc response to CMV responsible for protective immunity in seropositive donors, and to permit adoptive transfer of in vitro expanded CMV-specific Tc derived from bone marrow donors into immunocompetent HLA-matched BMT recipients to augment resistance to CMV. The immunodominant class I-restricted Tc response present in healthy seropositive individuals was found to be specific for a conserved CMV antigen introduced into the cytoplasm and presented shortly following viral penetration and uncoating, and did not require endogenous viral gene expression and protein synthesis. Thus, the protective immune response to CMV mediates lysis of virally-infected cells prior to virion assembly. Processing of viral proteins and access to presentation in the context of class I MHC molecules immediately following infection of target cells was selective for internal virion proteins, such as the tegument protein pp65. By contrast, presentation by infected cells of GB, the major CMV envelope protein, or IE, the major regulatory protein, was delayed due to a requirement for endogenous synthesis in infected cells, and CD8+ Tc specific for these proteins were detected in low frequency as compared to the immundominant response.


Blood | 1991

Cytotoxic T-Lymphocyte Response to Cytomegalovirus After Human Allogeneic Bone Marrow Transplantation: Pattern of Recovery and Correlation With Cytomegalovirus Infection and Disease

Pierre Reusser; Stanley R. Riddell; Joel D. Meyers; Philip D. Greenberg


Blood | 2002

Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation.

Pierre Reusser; Hermann Einsele; John Lee; Liisa Volin; Montserrat Rovira; Dan Engelhard; Jürgen Finke; Catherine Cordonnier; Hartmut Link; Per Ljungman


Blood | 1990

Cytomegalovirus infection after autologous bone marrow transplantation: occurrence of cytomegalovirus disease and effect on engraftment

Pierre Reusser; Lloyd D. Fisher; Buckner Cd; Thomas Ed; Joel D. Meyers


Blood | 1997

Cytomegalovirus-Specific T-Cell Immunity in Recipients of Autologous Peripheral Blood Stem Cell or Bone Marrow Transplants

Pierre Reusser; Rudolf Attenhofer; Holger Hebart; Claudine Helg; Bernard Chapuis; Herrmann Einsele


The Journal of Infectious Diseases | 1992

Phase I-II Trial of Foscarnet for Prevention of Cytomegalovirus Infection in Autologous and Allogeneic Marrow Transplant Recipients

Pierre Reusser; John G. Gambertoglio; Kathy Lilleby; Joel D. Meyers


Clinical Infectious Diseases | 1991

Cytotoxic T Cells Specific for Cytomegalovirus: A Potential Therapy for Immunocompromised Patients

Stanley R. Riddell; Pierre Reusser; Philip D. Greenberg


The Journal of Infectious Diseases | 1995

Failure of high-dose acyclovir to prevent cytomegalovirus disease after autologous marrow transplantation

Michael Boeckh; Theodore A. Gooley; Pierre Reusser; Buckner Cd; Raleigh A. Bowden


Clinical Microbiology and Infection | 2004

Ganciclovir prophylaxis to prevent CMV disease in kidney recipients undergoing anti-lymphocyte globulin treatment for acute rejection

Michael Dickenmann; Kairat Kabulbayev; Jürg Steiger; Gieri Cathomas; Pierre Reusser; Michael Tamm

Collaboration


Dive into the Pierre Reusser's collaboration.

Top Co-Authors

Avatar

Joel D. Meyers

University of Washington

View shared research outputs
Top Co-Authors

Avatar

Philip D. Greenberg

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar

Stanley R. Riddell

Fred Hutchinson Cancer Research Center

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Buckner Cd

University of Washington

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Gerhard Ehninger

Dresden University of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge